Inogen (INGN)
(Real Time Quote from BATS)
$8.12 USD
+0.05 (0.62%)
Updated Jun 5, 2024 02:45 PM ET
2-Buy of 5 2
C Value A Growth B Momentum A VGM
Brokerage Reports
Inogen, Inc [INGN]
Reports for Purchase
Showing records 1 - 20 ( 284 total )
Company: Inogen, Inc
Industry: Medical - Instruments
Provider: Zacks Investment Research
Analyst: Research Department
Company: Inogen, Inc
Industry: Medical - Instruments
Provider: Zacks Investment Research
Analyst: Research Department
Company: Inogen, Inc
Industry: Medical - Instruments
Provider: Zacks Investment Research
Analyst: Research Department
Company: Inogen, Inc
Industry: Medical - Instruments
Provider: Zacks Investment Research
Analyst: Research Department
Company: Inogen, Inc
Industry: Medical - Instruments
Provider: Zacks Investment Research
Analyst: Research Department
Company: Inogen, Inc
Industry: Medical - Instruments
Provider: Zacks Investment Research
Analyst: Research Department
Company: Inogen, Inc
Industry: Medical - Instruments
Provider: Zacks Investment Research
Analyst: Research Department
Company: Inogen, Inc
Industry: Medical - Instruments
Provider: Zacks Investment Research
Analyst: Research Department
Company: Inogen, Inc
Industry: Medical - Instruments
Provider: Zacks Investment Research
Analyst: Research Department
Company: Inogen, Inc
Industry: Medical - Instruments
Optimized Entry and Exit Levels for INGN 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Inogen, Inc
Industry: Medical - Instruments
Company: Inogen, Inc
Industry: Medical - Instruments
Provider: Zacks Investment Research
Analyst: Research Department
Company: Inogen, Inc
Industry: Medical - Instruments
Company: Inogen, Inc
Industry: Medical - Instruments
Provider: Zacks Investment Research
Analyst: Research Department
Company: Inogen, Inc
Industry: Medical - Instruments
Company: Inogen, Inc
Industry: Medical - Instruments
Provider: Zacks Investment Research
Analyst: Research Department
Company: Inogen, Inc
Industry: Medical - Instruments
Medical Technology: Suspending Coverage of 21 Companies
Provider: KeyBanc Capital Markets
Analyst: Research Department